A board to discuss the anticipated multiple sclerosis treatment Rituxan.
-
Anonymoose
- Family Elder
- Posts: 1156
- Joined: Tue Oct 09, 2012 6:33 am
Post
by Anonymoose » Mon Jul 13, 2015 6:30 am
http://www.ncbi.nlm.nih.gov/pmc/article ... 003053.pdf
Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally
ABSTRACT
Objective: We are conducting an open-label phase 1b study on the efficacy of intrathecal (IT) administration of rituximab, provided via an Ommaya reservoir, for the treatment of progressive multiple sclerosis (PMS). The objective of this initial study was to monitor B lymphocytes in peripheral blood (PB) and CSF from the first 10 patients 1 year posttreatment.
Methods: Dose titration was performed with daily escalation from 1 mg to 25 mg IT rituximab (n 5 3). Lymphocyte subpopulations were monitored daily during dose escalation in PB by flow cytometry and subsequently every 3 months for 1 year, after a total dose of 3 3 25 mg. PB B-lymphocyte subpopulations for the remaining patients (n 5 7) were monitored at regular intervals. CSF lymphocyte subpopulations for all patients were monitored by flow cytometry every 2–3 months.
Results: The PB B-lymphocyte count dropped rapidly after the first 2 injections (total dose of 3.5 mg IT rituximab) to undetectable levels. Three 25-mg doses given once per week depleted peripheral B lymphocytes entirely for the following 3–6 month period.
Conclusions: Monoclonal antibodies seem to rapidly redistribute to the peripheral compartment following IT injection. Ultra-low doses of rituximab given IT are sufficient to cause complete depletion of peripheral B lymphocytes, indicating that low-dose IT treatment has the potential to be effective in both the CNS and systemic compartments.
Classification of evidence: This study provides Class IV evidence that for patients with PMS, rituximab provided via an Ommaya reservoir depletes peripheral blood B lymphocytes. Neurol Neuroimmunol Neuroinflamm 2015;2:e79; doi: 10.1212/NXI.0000000000000079
More detail and graphs at link.
This would cost astronomically less than the traditional rituxan protocol...and no hours on end sitting in the infusion center. I would think this would open doors for a lot of people. I also think if I ever give rituxan another go, I'll save my $$ by going this route (last time did IT and IV). The LPs really aren't that bad...especially if you are saving $23000!
Good news!!

-
EricDrake
- Family Member
- Posts: 41
- Joined: Sun May 10, 2015 3:04 am
Post
by EricDrake » Mon Jul 13, 2015 9:09 am
Strange that they are still investigating rituximab in PMS, as far as I know they already had a trial for that:
http://www.ncbi.nlm.nih.gov/pubmed/19847908
I mean the old one shown some minor results but not such a big breakthrough and this new study does not mention anything about disease progression, strange.
-
Anonymoose
- Family Elder
- Posts: 1156
- Joined: Tue Oct 09, 2012 6:33 am
Post
by Anonymoose » Mon Jul 13, 2015 9:39 am
I think the new pms-rituxan studies are exploring the possibility that the treatment failed because IV administration barely penetrates the cns. The assumption is that it works in rrms because the bbb is open and therefore the rituxan can get into the cns. I believe this logic is also part of the suitability criteria for hsct protocols...no relapses, no joy or something like that. The new studies all have an IT component. There is conflicting information out there regarding the usefulness of rituxan in the cns. Some claim the cns B cells aren't cleared out by IT rituxan. Others claim they do. Based on successful use of IT rituxan for CNS lymphomas that were NOT managed by IV rituxan, I think the cns B cells are cleaned up by IT rituxan. I'm not a doctor though...just a rampant speculator.
To me, the importance of the linked paper isn't its effectiveness in controlling PMS. What's important is that for those that rituxan will help, it suddenly has become more financially achievable. Insurance usually won't pay for rituxan for ms so it's a huge out of pocket expense when administered the traditional way. The impossible becomes possible.
Rituxan is an old, relatively safe biologic. It doesn't carry the same risks big pharma's rituxan replacement for big $$$ does. This isn't the first study that has demonstrated the pb B cell depletion with low dose IT rituxan. The researchers are repeatedly making this point. I hope that translates into more affordable and effective treatments for pwms.
-
-
Temelimab safe even high dose
A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env...
- 0 Replies
- 299 Views
-
Last post by frodo
Thu Jul 18, 2019 3:41 am
-
-
- 0 Replies
- 355 Views
-
Last post by NHE
Thu Sep 26, 2019 2:41 am
-
-
High dose vitamin D exacerbates CNS autoimmunity
Replies: 3
First post
2019 Sep 1
Institute of Neuropathology, University Medical Center, Göttingen, Germany
High dose vitamin D exacerbates central nervous system...
Last post
Yes, they are talking about blood levels. But comparing the effects is really not conclusive, because rodans are likely to be more sensitive to...
- 3 Replies
- 286 Views
-
Last post by clarentine
Sat Oct 05, 2019 10:11 am
-
-
- 0 Replies
- 901 Views
-
Last post by MSUK
Wed Feb 14, 2018 6:13 am
-
-
Significant cognitive decline - will high dose steroids help
Replies: 9
First post
My mother is a 77 year old MS patient who was diagnosed with PPMS when she was 70. Looking back she'd had it for many years undiagnosed. Last...
Last post
again for whatever it may be worth, i prefer optimizing essential nutrient status to whatever degree possible, before getting into products that...
- 9 Replies
- 1113 Views
-
Last post by jimmylegs
Mon Dec 17, 2018 9:28 am
-
-
- 2 Replies
- 1784 Views
-
Last post by jimmylegs
Wed Dec 20, 2017 5:56 am
-
-
- 0 Replies
- 177 Views
-
Last post by NHE
Thu Aug 29, 2019 11:27 pm
-
-
Glia Cell
2019 May 17
Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Glial Cell AMPA Receptors in Nervous System Health, Injury and...
- 0 Replies
- 131 Views
-
Last post by Petr75
Mon Jul 01, 2019 8:31 am
-
-
Schwann cell
2019 Apr 22
Institut du Cerveau et de la Moelle Epinière-Groupe Hospitalier Pitié-Salpêtrière, INSERM, Sorbonne Universités, Université Pierre et...
- 0 Replies
- 149 Views
-
Last post by Petr75
Sat May 25, 2019 5:17 am